This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AQXP Aquinox Pharmaceuticals (AQXP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisTrendsBuy This Stock About Aquinox Pharmaceuticals Stock (NASDAQ:AQXP) Key Stats Today's Range$20.96▼$22.0750-Day Range$3.68▼$4.0352-Week Range$2.00▼$3.84Volume89,409 shsAverage Volume239,362 shsMarket Capitalization$508.70 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aquinox Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in developing novel therapeutics for chronic urological conditions by inflammation and pain. The company focuses on a library of novel compounds that activate SH2-containing inositol-5'-phosphatase 1 (SHIP1) to develop therapeutics for application in inflammation, inflammatory pain, and blood cancers. Its lead product candidate is Rosiptor (Leadership 301), a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome. The company was formerly known as Aquinox Pharmaceuticals (USA) Inc. and changed its name to Aquinox Pharmaceuticals, Inc. in January 2014. Aquinox Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Vancouver, Canada. Read More AQXP Stock News HeadlinesMirum Pharmaceuticals, Inc. (MIRM)February 11, 2024 | finance.yahoo.comWhy Aquinox Pharma (AQXP) Stock Might be a Great PickSeptember 24, 2023 | finance.yahoo.comUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent exposé on what he calls the $7.2 trillion 'Mar-a-Lago Trade.' Bloomberg warns it may cause 'a dire shift of fortunes for America.' Eifrig, who called the 2022 crash months early, says this event is already underway and could move as high as 10x from current levels. Over 500,000 paid subscribers follow his research. Access the full free broadcast before it comes down.July 2 at 1:00 AM | Stansberry Research (Ad)Aquinox Pharmaceuticals (AQXP) Stock Jumping in After-Hours Trading Following Earnings BeatJuly 26, 2023 | thestreet.comAquinox Pharma's lead product candidate flunks mid-stage trial in COPD; shares plummet 70%June 9, 2022 | seekingalpha.comSee More Headlines AQXP Stock Analysis - Frequently Asked Questions How were Aquinox Pharmaceuticals' earnings last quarter? Aquinox Pharmaceuticals Inc (NASDAQ:AQXP) posted its quarterly earnings data on Thursday, November, 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.43. What other stocks do shareholders of Aquinox Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aquinox Pharmaceuticals investors own include Novavax (NVAX), Bausch Health Cos (BHC), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), XOMA Royalty (XOMA), Alnylam Pharmaceuticals (ALNY) and NVIDIA (NVDA). Company Calendar Last Earnings11/08/2018Today7/02/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AQXP CIK1404644 Webwww.aqxpharma.com Phone604-629-9223FaxN/AEmployees8Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-30.13% Return on Assets-28.08% Debt Debt-to-Equity RatioN/A Current Ratio63.17 Quick Ratio63.17 Sales & Book Value Annual Sales$25 million Price / Sales20.35 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book6.99Miscellaneous Outstanding Shares23,540,000Free FloatN/AMarket Cap$508.70 million OptionableNot Optionable Beta-7.37 This page (NASDAQ:AQXP) was last updated on 7/2/2026 by MarketBeat.com Staff. From Our PartnersDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredWhat Happens to Your Assets If You Die Without a Will?Without a will, your state's intestacy laws decide how your assets are divided — a rigid formula that ignores ...SmartAsset | SponsoredUrgent exposé on the "Mar-a-Lago Trade"Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...Stansberry Research | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredThe pre-flight check for options tradersPilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Questions? Get started with MarketBeat. — Hello!Make the most of your MarketBeat account.37% completed. Great work!View a Company's Profile PageView Our Financial CalendarsView Today's Analyst RatingsRead Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant Alert Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
